Overview

A Crossover Bioequivalence Study of Olaparib Tablets, 150 mg (Lek Pharmaceuticals d.d.) and Lynparza® (Olaparib) Tablets 150 mg (AstraZeneca Pharmaceuticals LP), in Patients With BRCA Mutated Ovarian Cancer, Recurrent Ovarian Cancer or Metastatic B

Status:
Not yet recruiting

Trial end date:
2023-02-15

Target enrollment:

Participant gender:

Summary

This is a two-way crossover bioequivalence study between test and reference product in patients diagnosed with BRCA mutated ovarian cancer, recurrent ovarian cancer or metastatic breast cancer.

Phase:

Phase 1

Details

Lead Sponsor:

Sandoz

Treatments:

Olaparib